Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Portola Pharmaceuticals Inc.

Latest From Portola Pharmaceuticals Inc.

Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Appointments: IFPMA, German Merck, Ergomed, Spectrum, Astellas, Laboratoris Sanifit and Audentes Therapeutics

Appointment announcements this week include Greg Perry becoming the IFPMA’s new assistant director general, a new head of corporate affairs at German Merck, new CEOs at Ergomed and Spectrum, and other senior hires at Astella Americas, Laboratoris Sanifit, and a new board member at Audentes Therapeutics Inc.

Appointments BioPharmaceutical

Portola's Supplementary Approval Paves Way For Belated Bevyxxa Launch

Bevyxxa finally set to become the fifth new oral anticoagulant on the US market, but in a unique, niche indication of acute medical illness.

Approvals Manufacturing

Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy

Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Portola Pharmaceuticals Inc.
  • Senior Management
  • William Lis, CEO
    Mardi C Dier, EVP, CFO
    John T Curnutte, MD, PhD, EVP, R&D
    Tao Fu, EVP, Chief Commercial & Bus. Officer
  • Contact Info
  • Portola Pharmaceuticals Inc.
    Phone: (650) 246-7000
    270 E. Grand Ave.
    So. San Francisco, CA 94080